ClinConnect ClinConnect Logo
Search / Trial NCT06901544

Capillary Leak Index as a Prognostic Indicator for Post-Operative Abdominal Sepsis in Critically Ill Patients

Launched by AIN SHAMS UNIVERSITY · Mar 27, 2025

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Capillary Leak Index Secondary Abdominal Sepsis Sepsis Prognostic Value Good Indicator Mortality Intensive Care Unit Icu

ClinConnect Summary

This clinical trial is studying a new method called the Capillary Leak Index (CLI) to see if it can help predict the risk of severe infections after surgery in critically ill patients. Specifically, the researchers want to find out if measuring the CLI can provide early warning signs for post-operative abdominal sepsis, which is a serious infection that can occur after surgeries involving the abdomen, like those for appendicitis or intestinal blockages.

To participate in this study, patients must be at least 18 years old and have developed post-operative abdominal sepsis, which means they have an infection in their abdomen after surgery. They should also expect to stay in the Intensive Care Unit (ICU) for at least 48 hours. However, some patients may not be eligible if they have certain health conditions, such as severe liver or kidney disease, are pregnant, or have advanced cancer. Those who participate will undergo tests to measure the CLI and be closely monitored during their recovery. This study is currently not recruiting participants, but it aims to improve how doctors can predict and manage infections in critically ill patients after surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age: ≥18 years old presented with Post-operative intra-abdominal sepsis due to secondary peritonitis.
  • Sex: Both sexes.
  • Post-Operative secondary peritonitis eg. Perforated viscus and abdominal abscess.
  • Estimated length of ICU stays ≥48 hrs.
  • Exclusion Criteria:
  • Patient refusal.
  • Advanced Liver diseases According New MELD score ≥ 20 )Kamath et al.,2001)
  • Renal diseases (Moderate decrease in GFR 30-59 ml/min/1.73m²--Severe decrease in GFR 15-29 ml/min/1.73m²--Kidney failure less than 15 ml/min/1.73m² or on Hemodialysis).
  • Pregnancy.
  • Primary peritonitis.
  • Tertiary peritonitis.
  • Mortality within first 48hrs of ICU admission.
  • Advanced malignancy ( Stage III localized malignancy with spreading lymph nodes Stage IV spreading to Other parts of the body such as to the liver, lungs and bones).

About Ain Shams University

Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.

Locations

Cairo, , Egypt

Patients applied

0 patients applied

Trial Officials

Ahmed M Ahmed, MD.

Study Director

Ain shams University Faculty of medicine

Hanaa A El-Gendy, MD

Study Chair

Ain Shams University Faculty of medicine

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported